출생전 및 신생아 유전자 검사 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global prenatal and newborn genetic testing market size is expected to reach USD 21.97 Billion in 2034 from USD 7.93 Billion in 2025, growing at a CAGR of 11.99% during 2026-2034.This market is expanding as healthcare systems place greater emphasis on early identification of genetic conditions during pregnancy and shortly after birth. Prenatal genetic testing can help assess the risk of selected chromosomal and inherited disorders, while newborn genetic testing supports the early detection of conditions that may benefit from timely intervention. Growing awareness of reproductive health, improvements in screening technologies, and increased availability of genetic counseling are supporting demand. Noninvasive prenatal testing has also attracted attention because it analyzes cell-free fetal DNA circulating in maternal blood to screen for certain chromosomal conditions without requiring an invasive sampling procedure.

Market growth is driven by advancements in DNA sequencing, molecular diagnostics, and laboratory automation. Healthcare providers are increasingly integrating genetic screening into prenatal care and newborn screening programs where appropriate. Expanding public health initiatives, improved diagnostic infrastructure, and rising awareness of inherited disorders are also contributing to adoption. Diagnostic laboratories are investing in advanced testing platforms that can analyze genetic information with improved efficiency. At the same time, growing collaboration among healthcare professionals, biotechnology companies, and public health organizations is supporting the development of broader testing panels and improved pathways for confirmatory diagnosis.

The future prospects of this market will be shaped by improvements in test accuracy, wider access to genetic counseling, and the development of more comprehensive screening approaches. Advances in sequencing technologies may enable the identification of a broader range of genetic conditions, while improved bioinformatics tools could support more efficient interpretation of results. Greater integration of screening programs with follow-up diagnostic services may help ensure that families receive appropriate clinical guidance. However, ethical considerations, privacy concerns, unequal access, and the potential for uncertain or incidental findings require careful management. Clear consent procedures, clinical oversight, and responsible communication will remain essential to sustainable growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product Type

• Consumables
• Instruments

By Screening

• Non-Invasive Prenatal Testing
• Chronic Villus Sampling
• Amniocentesis
• Maternal Serum Screening
• Others

By Disease

• Downs Syndrome
• Phenylketonuria
• Cystic Fibrosis
• Sickle Cell Anemia
• Others

By End User

• Hospital
• Maternity And Specialty Clinics
• Diagnostic Centers

COMPANIES PROFILED

• Natera, Illumina, Labcorp, Quest Diagnostics, Roche, Thermo Fisher Scientific, Fulgent Genetics, Invitae, Myriad Genetics, BillionToOne, BGI, Natera Panorama, Eurofins, PerkinElmer, Revvity, GeneTech, Ariosa Diagnostics, CooperSurgical, Yourgene Health, Centogene

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET: BY SCREENING 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Screening
• 5.2. Non-Invasive Prenatal Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Chronic Villus Sampling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Amniocentesis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Maternal Serum Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET: BY DISEASE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease
• 6.2. Downs Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Phenylketonuria Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cystic Fibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Sickle Cell Anemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospital Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Maternity And Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product Type
  • 8.2.2 By Screening
  • 8.2.3 By Disease
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product Type
  • 8.3.2 By Screening
  • 8.3.3 By Disease
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product Type
  • 8.4.2 By Screening
  • 8.4.3 By Disease
  • 8.4.4 By End User
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product Type
  • 8.5.2 By Screening
  • 8.5.3 By Disease
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product Type
  • 8.6.2 By Screening
  • 8.6.3 By Disease
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PRENATAL AND NEWBORN GENETIC TESTING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Natera
  • 10.2.2 Illumina
  • 10.2.3 Labcorp
  • 10.2.4 Quest Diagnostics
  • 10.2.5 Roche
  • 10.2.6 Thermo Fisher Scientific
  • 10.2.7 Fulgent Genetics
  • 10.2.8 Invitae
  • 10.2.9 Myriad Genetics
  • 10.2.10 BillionToOne
  • 10.2.11 BGI
  • 10.2.12 Natera Panorama
  • 10.2.13 Eurofins
  • 10.2.14 PerkinElmer
  • 10.2.15 Revvity
  • 10.2.16 GeneTech
  • 10.2.17 Ariosa Diagnostics
  • 10.2.18 CooperSurgical
  • 10.2.19 Yourgene Health
  • 10.2.20 Centogene